{"DataElement":{"publicId":"4364111","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Active Coronary Disease Less Than 12 Month Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 12 months prior to first study drug administration.","longName":"PT_EC_1009","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4363957","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Active Coronary Disease Less Than 12 Month","preferredDefinition":"Earlier in time or order._Preceding all others in time or space or degree._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research._Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._Exerting influence or producing an effect; taking part in an activity._An imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels._A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status._A number with no fractional part, including the negative and positive numbers as well as zero.::12_One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.","longName":"4363919v1.0:4363920v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"4363919","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration","preferredDefinition":"Earlier in time or order.:Preceding all others in time or space or degree.:Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.:Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","longName":"4363919v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC994407-07F4-3164-E040-BB89AD431632","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"ONEDATA","dateModified":"2014-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4363920","version":"1","preferredName":"Active Coronary Artery Disease Less Than Integer::12 Month","preferredDefinition":"Exerting influence or producing an effect; taking part in an activity.:An imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.:A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.:A number with no fractional part, including the negative and positive numbers as well as zero.::12:One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.","longName":"4363920v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Active","conceptCode":"C45329","definition":"Exerting influence or producing an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Coronary Artery Disease","conceptCode":"C26732","definition":"Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Month","conceptCode":"C29846","definition":"One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC994407-0808-3164-E040-BB89AD431632","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"ONEDATA","dateModified":"2014-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9A280D-10E9-F11E-E040-BB89AD437627","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"DWARZEL","dateCreated":"2014-06-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"PT_EC_1009","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Active coronary artery diseas","type":"Preferred Question Text","description":"Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 12 months prior to first study drug administration.","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease, as defined by the New York Heart Association Functional Classification, or history of myocardial infarction within 6 months prior to first dose with study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient had acute coronary syndrome within 6 months prior to starting treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient had myocardial infarction or unstable angina within 6 months prior to the first dose of ZEN003694?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9B2610-95EA-3899-E040-BB89AD4338F9","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2021-08-30","changeDescription":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}